MedPath

and medium-term outcomes of novel biologics and lightweight synthetic mesh for ... - PubMed

A study evaluated the effectiveness of a novel composite biologics (UBM/SIS) in laparoscopic inguinal hernia repair (LIHR) compared to a synthetic mesh. The four-year follow-up showed no significant difference in hernia repair effectiveness rates (100% vs 95.45%) and lower incidence of postoperative complications with UBM/SIS. Trial registration: ChiCTR1800020173.


Reference News

and medium-term outcomes of novel biologics and lightweight synthetic mesh for ... - PubMed

A study evaluated the effectiveness of a novel composite biologics (UBM/SIS) in laparoscopic inguinal hernia repair (LIHR) compared to a synthetic mesh. The four-year follow-up showed no significant difference in hernia repair effectiveness rates (100% vs 95.45%) and lower incidence of postoperative complications with UBM/SIS. Trial registration: ChiCTR1800020173.

© Copyright 2025. All Rights Reserved by MedPath